Publicaties

1 - 10 of 32 resultaten

Sorteren op
Zoek term:

Enzyme variation in Trypanosoma brucei spp. I. Evidence for the sub-speciation of Trypanosoma brucei gambiense Instituut voor Tropische Geneeskunde

A Tait, EA Babiker, Dominique LE RAY
Three groups of stocks of Trypanosoma brucei ssp, defined by the criteria of host, human serum resistance and place of isolation as T. b. gambiense, T. b. brucei (Nigeria) and T. b. brucei/rhodesiense (non-gambiense, Uganda) were screened for electrophoretic variation at 20 enzyme loci. One enzyme (Peptidase C) was found to differentiate all T. b. gambiense stocks from the other T. brucei stocks and, taken together with specific variants of 5 ...

Development of new serodiagnostic tests for African trypanosomiasis due to Trypanosoma evansi and Trypanosoma brucei gambiense Instituut voor Tropische Geneeskunde

Stijn Rogé
African trypanosomiases are neglected parasitic diseases that perpetuate poverty through their burden on public health and agriculture. Gambiense human African trypanosomiasis (HAT) is caused by Trypanosoma brucei (T.b.) gambiense in West and Central Africa. Surra is caused by Trypanosoma evansi, affects wild and domestic animals and leads to economic losses for the farmers.
Serodiagnosis of HAT and surra is performed with agglutination ...

Heme-deficient metabolism and impaired cellular differentiation as an evolutionary trade-off for human infectivity in Trypanosoma brucei gambiense Instituut voor Tropische Geneeskunde

Eva Horáková, Laurence Lecordier, Paula Cunha, Roman Sobotka, Piya Changmai, Catharina J. M. Langedijk, Jan Van Den Abbeele, Benoit Vanhollebeke, Julius Lukes

Resistance to African trypanosomes in humans relies in part on the high affinity targeting of a trypanosome lytic factor 1 (TLF1) to a trypanosome haptoglobin-hemoglobin receptor (HpHbR). While TLF1 avoidance by the inactivation of HpHbR contributes to Trypanosoma brucei gambiense human infectivity, the evolutionary trade-off of this adaptation is unknown, as the physiological function of the receptor remains to be elucidated. Here we show ...

Population genetics of Trypanosoma brucei gambiense in sleeping sickness patients with treatment failures in the focus of Mbuji-Mayi, Democratic Republic of the Congo Instituut voor Tropische Geneeskunde

Patient Pyana Pati, Modou Sere, Jacques Kabore, Thierry De Meeûs, Annette MacLeod, Bruno Bucheton, Nick Van Reet, Philippe Büscher, Adrien Marie Belem, Vincent Jamonneau, et al.

Human African trypanosomiasis (HAT) in the Democratic Republic of the Congo (DRC) is caused by the protozoan Trypanosoma brucei gambiense. Until recently, all patients in the second or neurological stage of the disease were treated with melarsoprol. At the end of the past and the beginning of the present century, alarmingly high relapse rates in patients treated with melarsoprol were reported in isolated HAT foci. In the Mbuji-Mayi focus of ...

Characterization of Trypanosoma brucei gambiense variant surface glycoprotein LiTat 1.5 Instituut voor Tropische Geneeskunde

Liesbeth Van Nieuwenhove, Stijn Rogé, Veerle Lejon, Y Guisez, Philippe Büscher
At present, all available diagnostic antibody detection tests for Trypanosoma brucei gambiense human African trypanosomiasis are based on predominant variant surface glycoproteins (VSGs), such as VSG LiTat 1.5. During investigations aiming at replacement of the native VSGs by recombinant proteins or synthetic peptides, the sequence of VSG LiTat 1.5 was derived from cDNA and direct N-terminal amino acid sequencing. Characterization of the VSG ...